Drug Patents owned by Bdsi

1. List of Belbuca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Treatement of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

2. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(9 years from now)

US9522188 BDSI Abuse resistant transmucosal drug delivery device
Apr, 2035

(12 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

3. List of Elyxyb drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572819 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US10376527 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US9949990 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US10722456 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US10799517 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US9795620 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 5, 2023

Drugs and Companies using CELECOXIB ingredient

Market Authorisation Date: 05 May, 2020

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: SOLUTION;ORAL

More Information on Dosage

4. List of Onsolis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597288 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 16 July, 2009

Treatment: Management of breakthrough pain in patients with cancer

Dosage: FILM;BUCCAL

More Information on Dosage

5. List of Symproic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(3 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(4 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(8 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2022

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in